08-MAR-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3929 345 194 96 36 9 02/06/2019 472 182
Screened at PD     1436 186 119 59 26 6      
Pre-Screened prior to PD     2473 139 65 31 9 3      
Treatment-naive     20 20 10 6 1 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     528 30 16 9 6 1      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2112 357 144 73 29 5      
Screened at PD     1204 211 114 58 26 5      
Pre-Screened prior to PD     832 122 19 8 1 0      
Treatment-naive     20 20 10 7 2 0      
After PD on a Lung_MAP Sub-Study     56 4 1 0 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     315 315 124 59 25 5      
S1900G     34 6 2 1 0 0      
S1900J     17 8 4 3 2 0      
S1900K     36 28 14 10 2 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     594 99 63 38 12 3      
Initial sub-study registrations     582 99 63 38 12 3      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 68 68 47 28 9 2 05/22/2025 354 113
Docetaxel plus Ramucirumab Y   36 36 24 15 6 2      
Cemiplimab plus Docetaxel and Ramucirumab Y   32 32 23 13 3 0      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 24 7 3 1 0 0 05/05/2023 342 109
Capmatinib + Osimertinib + Ramucirumab Y   14 6 3 1 0 0      
Capmatinib + Osimertinib Y   10 1 0 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 4 3 2 1 1 1 11/19/2024 242 80
Amivantamab Hyaluronidase Y   4 3 2 1 1 1      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 24 21 11 8 2 0 08/08/2024 270 89
Tepotinib + Ramucirumab Y   16 14 8 6 2 0      
Tepotinib Y   8 7 3 2 0 0